02
2015-12
The List of 10th Anniversary of China's Top 50 Most Valuable Enterprises to Invest in 2015
The selection of China’s top 50 most valuable investment enterprises was initiated by Zero2IPO Group.It is the first annual selection event focusing on high-growth enterprises in the investment community.
17
2015-07
Recently, a new-generation AR antagonist, proxalutamide, independently developed by Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") receives initiation funding for special project of significant novel drugs development in "13th Five-Year plan".
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn